NR1H4 and Hepatic steatosis: Support comes from studies investigating the effects of FXR activation by 6-ethyl-chenodeoxycholic acid, a potent activator of FXR, in rats with diabetes mellitus, obesity, insulin resistance, and liver steatosis [106].